Headquartered in Planegg-Martinsried near Munich/Germany, 4SC is an innovative biopharmaceutical company with a strong focus on product development in oncology.

We develop novel small molecule drugs for the treatment of cancer in indications with a high unmet medical need and significant economic potential.

We wish to offer affected patients treatment options that are more effective and better tolerated to provide a better quality of life.

Our product pipeline comprises promising drug programs at various stages of clinical development. We are focusing on fields of research that contribute to the development and persistence of cancer.

Learn more about 4SC

Our values, experience and commitment are the keys to developing better drugs for patients with cancer.

We are curious by nature and seek to address fundamental questions in cancer biology which we hope will result in better drugs for patients with cancer.

We are united by our shared values, and a sense of fairness and curiosity.

Experience and expertise lead to better decision making, informative data and peer and patient recognition – the foundation for our success.

Continuous exchange and open communication create value and long-standing partnerships.

Products

Clinical Trials

Investors

News

4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA

4SC: Landmark RESMAIN study data presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

4SC: RESMAIN study data to be presented at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting

Events

4SC AG: Developing innovative drugs for cancer patients